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ABSTRACT
Proton pump inhibitors (PPIs) are commonly prescribed to treat stomach acid
related illnesses, but increase the risk of hospital acquired infections. Measuring
hospital PPI overuse trends and provider willingness to adopt PPI reduction
interventions can inform the feasibility of reducing PPI overuse.
We: (1) interviewed physicians, pharmacists and IT leaders to determine options
for hospital PPI reduction, (2) analyzed electronic health record data to determine
patterns of PPI overuse, and (3) surveyed providers regarding their willingness to adopt
PPI reduction interventions.
PPI use was inappropriate in 32% of inpatient encounters locally and 38%
nationally. ICU exposure increased the odds of inappropriate use by 53% locally and
21% nationally. Common reasons for inappropriate PPI use were stress ulcer
prophylaxis and symptom management. Providers rarely consider PPI adverse events
or discuss these risks with patients, but are willing to adopt PPI reduction interventions.
Reducing PPI overuse in the hospital setting is feasible.
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INTRODUCTION
Each year, hospital-associated (nosocomial) infections in the US are
estimated to result in 2 million infections, 100,000 deaths1, and expenditures
upwards of $10 billion2. Nosocomial infections are increasingly recognized as
major threats to public health, and they are the targets of a number of large
national initiatives including the Steering Committee for the Prevention of Health
Care-Associated Infections led by the US Department of Health and Human
Services3.
Proton pump inhibitors (PPIs) are given to about 39% of all hospitalized
patients in the US4–6 (Table 1) and to about 43% of patients worldwide for a
variety of gastric acid related disorders, according to published studies on PPI
use. The initial presumptions of PPI safety were derived from the controlled
environments of clinical trials, a safety profile that is proving to be far from
accurate in real world practice. A number of recent studies have reported
findings regarding PPI safety, including an increased risk of infections in both
hospital and community settings. PPIs are second to antibiotics as the leading
cause of acute interstitial nephritis7, increase risk of Vitamin B12 deficiency8 with
an odds ratio (OR) of 4.45, and have consistently been found to increase the risk
of hip fractures9–11 with a significant dose response effect, with the highest ORs
(2.5 to 2.65) for hip fractures found in long term or high dose groups. More
recently PPIs have even been found to increase the risk of End Stage Renal
Disease12 (OR 1.9) and of total mortality13 (OR 1.75).
In terms of hospital acquired infections, the strongest and most consistent
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Table 1. Studies of PPI Overuse
First Author
Eid
Gupta
Ladd
Reid
Reid

Year
2010
2006
2010
2008
2008
2003Thomas
2006
US inpatient mean
Glew
2007
Heidelbaugh
2010
Patterson
2011
Rotman
2002
Rotman
2009
Batuwitage
2007
Bustamante
2012
Chia
2011
Chavez-Tapia
2008
e Burgos
2003
Kelly
2014
Kroll
1999
Naunton
2010
Noguerado
2000
Pasina
2011
Ramirez
2010
Villamanan
2015

Country
US
US
US
US
US

Setting
Inpt
Inpt
Inpt
Inpt
Inpt

US

Inpt discharge Rx

US
US
US
US
US
UK
Peru
Singapore
Mexico
Spain
UK
Denmark
Australia
Spain
Italy
Spain
Spain

total #

2094
9875
6,592,100

Nursing facility
98
Outpt
Nursing facility
1381
Outpt 772,000,000
Outpt 919,000,000
Outpt
271
Inpt
Inpt
1025
Outpt liver clinic
Outpt liver clinic
Inpt
447
Outpts w/ dyspepsia
331
Inpt
Inpt
1155
Inpt
328
Inpt

Overall mean (SD)
PPI: Proton Pump Inhibitor: Inpt: Inpatient; Outpt: Outpatient; sd: Standard Deviation

# on PPI
400

3962
922,000

% on PPI
70.0
30.0
40.0
14.0

29348
60
946
30,000,000
84,000,000
66
417
477
243
412

38.5
61.0
80.0
4.0
9.2
24.0
46.5

58.0
28.0
200
209
647

40.3
82.6

294
42.7
(SD= 25.6)

% inappropriate
61.0
73.0
76.0
50.0
73.0
69.0
67.0
50.0
36.1
65.3
63.0
63.0
54.0
54.6
54.1
53.9
63.7
27.0
76.0
62.9
72.2
63.2
61.0
64.0
60.3
(SD=12.0)
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associations have been found with increasing risk of clostridium difficile infection
and nosocomial pneumonia. An OR of 2.2 was found for developing clostridium
difficile infection in those receiving a PPI compared to those that were not in a
2015 retrospective cohort of 10,000 patients14. Similarly, an OR of 2.1 in PPIexposed patients for development of clostridium difficile infection was detected in
a study of 1200 hospitalized patients in 200415. An adjusted OR of 2.7 was
detected in the PPI exposed group for developing hospital acquired pneumonia
in 201416. Finally, an OR of 2.1 was shown for developing pneumonia in PPIexposed ambulatory patients in a meta-analysis of 26 observational and
prospective studies including over 6 million participants17. The mechanism for
this increased infection risk is believed to be that PPIs decrease the gut’s ability
to sterilize foreign bacteria within an acidic environment18,19.
Since their introduction in 1989, the use of PPIs worldwide has increased
at an astonishing rate. In 2009 PPIs were prescribed 113.4 million times and
generated $13.9 billion in sales20. Analyses of PPI prescription trends indicate
that PPI use has more than doubled in the US from 2001-2002 to 2009-2010 in
both outpatient21 and emergency department settings22. In Australia a 1318%
increase in PPI use was found between 1995 and 2006, with no corresponding
increase in gastroesophageal reflux disease (GERD) incidence23. Similar
findings of increasing PPI use with no associated change of indications or
disease prevalence have been published in the UK24 and Denmark25.
The official FDA indications for prescribing PPIs are fairly specific, limited,
and vary by brand26–30. Lansoprazole, which has the broadest FDA approved
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indication list, is approved for the treatment of: (1) symptomatic GERD, (2) acute
and chronic erosive esophagitis, (3) helicobacter pylori infection, (4) acute and
chronic duodenal ulcers, (5) prevention and treatment of non-steroidal antiinflammatory drug (NSAID)-induced gastric ulcers, and (6) Zollinger Ellison
syndrome. Other PPIs, such as esomeprazole, pantoprazole, and rabeprazole,
are approved for less than half of these indications (Table 2).
Expert opinion on the other hand, as outlined by professional medical society
guidelines, recommends PPIs for a much broader list of indications and
sometimes an inconsistent list of indications across societies. According to
clinical guidelines published by the American Gastroenterological Association
(AGA) and the American College of Gastroenterology (ACG), PPIs are
recommend as part of the first line therapy in the treatment of a number of acute
and chronic medical conditions, including: (1) acute upper GI bleeding31, (2)
erosive esophagitis/gastritis32, (3) eosinophilic esophagitis33,(4) dyspepsia in
helicobacter pylori negative patients less than 60 years old34,35, and (5)
helicobacter pylori infection36. Professional societies also recommend PPIs for
the first line treatment of GERD37,38, although alternative medications such as H2
receptor antagonists (H2RAs), especially famotidine, have also been shown to
be highly effective at treating GERD39, and they do not have as strong of an
association with nosocomial infections40. For other indications there is clear
disagreement between professional societies. The ACG recommends PPIs use
for the prevention of NSAID-induced gastric ulcers41 and for chemoprevention in
Barrett’s esophagus42, whereas these practices are discouraged by the AGA43.
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Table 2. FDA and Professional Society Indications for PPI Prescribing
Prof
societies

FDA Indications
Indication
Treatment of
symptomatic GERD
Treatment of erosive
esophagitis
Maintenance of healed
erosive esophagitis
Eradication of H pylori
infection
Prevention of NSAIDinduced gastric ulcer
Treatment of NSAIDinduced gastric ulcer
Treatment of gastric
ulcer
Treatment of duodenal
ulcer
Maintenance of healed
duodenal ulcer
Treatment of Zollinger
Ellison syndrome
Treatment of
Eosinophilic Esophagitis
Treatment of H Pylori
negative Dyspepsia in
age <60
Chemoprevention in
barrett's esophagus
Treatment of GI bleeding
from peptic ulcer disease

Esomeprazole Lansoprazole Omeprazole
x

Pantoprazole Rabeprazole ACG

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

x

AGA

x

x

x

x

x

x

x

x
x

x

x

x

x
x

x

x
x

x
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In the most common conditions for which patients are prescribed PPIs,
including dyspepsia34, non-erosive GERD, and helicobacter pylori infection, PPI
therapy is recommended only for a limited trial period. For example, in nonerosive GERD treatment, which is by far the most common PPI indication, the
AGA only recommends short term PPI therapy (4 to 8 weeks) followed by on
demand treatment to minimize the risks of long term therapy44. Nonetheless,
31% of patients given a prescription for GERD continue to take their PPI for at
least a year, according to one large study45. It has also been shown that
outpatient physicians only discuss the duration of PPI therapy with their patients
10% of the time when prescribed for dyspepsia46. There is also evidence that
outpatient physicians rarely make efforts to taper or discontinue PPIs once they
are started for treatment of GERD symptoms. Of 259 charts reviewed from an
outpatient US clinic in 2009, 32% of patients received PPI prescriptions, 83% for
GERD, and there was no evidence of any attempt to taper or stop therapy after
symptom control47. For dyspepsia, treatment with PPIs is only recommended in
certain age groups (<55-60) without other concerning symptoms and only as a 46 week treatment trial in the context of a more complex evaluation algorithm 35.
Safer alternatives to PPI therapy in the treatment of dyspepsia have also been
studied and found to be effective, such as H2RAs and prokinetics48, but to date
no randomized trial has been performed comparing the efficacy of these
dyspepsia treatments to PPIs. An estimated 76% of PPI prescriptions for
dyspepsia are not consistent with guidelines49.
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Despite the relatively broad PPI indications recommended by expert
opinion guidelines from the ACG and AGA, PPIs still appear to be grossly
overprescribed by providers. At least 21 studies have been published worldwide
on trends of PPI overuse from both inpatient and outpatient settings4–6, 21, 50–65
(Table 2). The average percent of PPI orders deemed inappropriate from these
studies is 60%, and if we only consider studies of hospitalized patients in the US
the average goes up to 67%. The PPI overuse epidemic has been well
documented in the US, UK, Mexico, Peru, Singapore, Spain, Italy, Denmark, and
Australia. A number of very large studies on acid suppressive therapy (which
includes H2 receptor antagonists) have also been published, including a review
of 170,000 patients, of which only 61% of patients had a relevant upper
gastrointestinal (GI) diagnosis that would justify a PPI prescription66. In one
study, a cost of $1.5 million was attributed to PPI overuse in a group of 1,000
hospitalized patients in the US50. Most of these studies use an inclusive
combination of FDA approved indications and professional society guideline
recommendations for creating a list of appropriate indications to determine PPI
appropriateness.
Despite a paucity of evidence for the practice, PPIs are also commonly
used for stress ulcer prophylaxis (SUP) in hospitalized patients. Multiple chart
review studies, including 3 from the US, have found SUP in non-critically ill
inpatients to be the most common reason for inappropriate PPI use, with a
majority of these cases having no risk factors for stress ulcers or bleeding5,67–72.
Furthermore, between 52 and 55% of non-critically ill patients that receive PPIs
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for SUP are discharged with a new unnecessary PPI prescription 71,73. The
practice of routine prophylaxis of non-critically ill hospitalized patients with PPIs is
not recommended by professional societies and has no supporting evidence.
The common practice of routine PPI use for stress ulcer prophylaxis in
critically ill patients has also been proven to be non-beneficial. The largest and
most recent study on stress ulcer prophylaxis in critically ill patients randomized
3,298 adult ICU patients to receive either intravenous PPI or placebo and found
no difference in the primary outcome of 90 day mortality between the groups 74.
This finding is consistent with a prior meta-analysis of 27 similar smaller studies
(N=1,971), which found no statistically or clinically significant reduction in
mortality or reduction in GI bleeding75. Studies have also found that patients
started on PPIs in the intensive care unit are commonly discharged with
instructions to continue these medications as outpatients indefinitely73,76,77. To
make matters worse, once started, PPIs can be very difficult to stop due to a PPI
withdrawal effect known as rebound acid hypersecretion78. After 8 weeks of
omeprazole therapy both basal and maximal acid output have been found to be
significantly higher than baseline (up to 82% and 28% respectively)79,80. Forty
four percent of healthy volunteers experienced acid regurgitation, dyspepsia, or
heartburn from stopping a PPI after 8 weeks of administration, far more than the
control group (15%), according to a randomized, double blinded controlled trial81.
The standard approaches to combating infectious disease outbreaks in
hospital settings tend to involve interventions such as vaccinations, prophylactic
medications, isolation precautions and hand hygiene. For clostridium difficile
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infections, one of the most common nosocomial infections, reduction
interventions such as hand hygiene82,83 and chlorhexidine84,85 bathing have failed
to consistently reduce infection rates in clinical trials. Despite the widespread
adoption of standard nosocomial infection reduction strategies, the incidence of
clostridium difficile in hospitalized patients has risen substantially86. Given the
strong association between PPIs and nosocomial infections, and the evidence of
PPI overuse in hospitalized patients, reducing the exposure of patients to
unnecessary PPIs during their hospitalization could be a practical means to
addressing the nosocomial infection epidemic. Interventions including provider
education87, patient education46, and clinical decision support88 have been shown
to effectively reduce inappropriate PPI prescription practices. Similar
interventions have also worked for reducing inappropriate use of other
medications, such as antibiotics for the treatment of respiratory tract infections89.
Given the tremendous morbidity, mortality and costs associated with
nosocomial infection, the benefits of reducing the exposure of patients to
medications that increase the risk of these infections could be profound. The
cost reduction from a successful PPI reduction strategy would decrease the cost
of unnecessary PPI prescriptions as well as the costs due to the treatment and
complications of nosocomial infections. Furthermore, the development of a
feasible intervention strategy to modify potentially harmful PPI prescription
behavior could prove useful for reducing the over-prescription of other
pharmaceuticals.
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The goals of this research are to quantify the current extent of
unnecessary PPI use in the hospital setting and to develop an intervention
strategy for hospitals to reduce nosocomial infection risk by improving PPI
prescription practices. We will accomplish these goals with three specific aims:
1. Determine the feasibility of implementing a future successful PPI
reduction intervention and inform its design through in-depth interviews
with local content and systems experts from pharmacy, information
technology, and Internal Medicine.
Successful implementation of systems-based changes must be
informed by and developed in collaboration with local content
experts, hospital policy leaders, and relevant stakeholders. We
must consider the socio-technical barriers and practical limitations
to making systems-based changes at our institution to develop and
implement a successful approach to increasing appropriate PPI
prescribing among providers. Consideration of the opinions and
knowledge of experts responsible for the distribution of PPIs will be
the basis for determining the feasibility and design of implementing
a future intervention to reduce inappropriate PPI prescribing.
2. Estimate the extent of PPI overuse in both the local University of New
Mexico Hospital (UNMH) setting and nationally through analysis of
electronic health record (EHR) data.
To design a future study to investigate the effect of a PPI
reduction initiative on the prescription habits of inpatient providers,
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we will need to measure the rate of appropriate versus
inappropriate PPI prescription over time. Such a determination of
PPI appropriateness must be shown to be valid and reliable. A
chart review process will also be used to validate the EHR data
trends and to determine the feasibility and reliability of assessing
the appropriateness of PPI prescriptions.
3. Explore the current knowledge of UNMH health care providers
regarding appropriate PPI indications and their attitudes towards a PPI
reduction initiative using a brief survey.
To assess the need for educational interventions as part of a
future inappropriate PPI reduction intervention, we must first
quantify the extent of the problem in terms of local provider
knowledge gaps regarding PPI risks and indications. Educational
interventions to successfully improve evidence-based practice
should be designed to target specific knowledge gaps. From a
feasibility standpoint, we must also determine the willingness of
local providers to collaborate in adopting systems-based changes
that will directly affect their practices.

METHODS
Aim 1- Interviews
The objective of this aim was to inform the development of an intervention
to reduce inappropriate PPI use that is feasible, safe and effective. To

12
accomplish this aim we conducted in depth semi-structured interviews with
carefully selected local experts designed to explore their knowledge and views
regarding content, design and proposed systems-based changes to reduce
inappropriate PPI prescriptions.
We conducted semi-structured interviews using 3 separate interview
guides designed for experts and leaders in: pharmacy, information technology,
and Internal Medicine. Each interview guide was tailored to address potential
future intervention design strategies and implementation barriers relevant to each
respective expert category (See Appendix A). Interviews were designed to last
up to 60 minutes each.
(1) The pharmacy interviews addressed interest, feasibility, and logistics in
implementing a pharmacy driven process for daily chart audits of
hospitalized patients to assess appropriateness of PPI prescriptions
and suggest alternatives to providers for inappropriate cases.
(2) The information technology interviews addressed interest and logistics
of developing a PPI order “care-set” in the electronic medical record
that provides clinical decision support text informing providers of
evidence based PPI indications and providing convenient order options
for safe alternatives to PPIs.
(3) The Internal Medicine physician interviews addressed expert opinion
on appropriate indications for inpatient PPI prescriptions and
appropriate algorithms for antacid alternatives including H2 receptor
antagonists and acid neutralizers such as Tums, Maalox and Mylanta.
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Each interview guide was updated as new information was learned from
previous interviews – that is, what we learned in earlier interviews suggested new
questions for following interviews within and across groups of experts. Up to 3
individuals in each of the 3 expert categories were identified and approached for
interviews (See Appendix A). A diverse selection of experts was approached for
interviews using criteria that ensure a range of seniority, age and gender among
the interviewees. Individuals with expertise in the subject matters relevant to the
three expert categories were recruited for the interviews. Individuals holding
leadership positions within the institution in their respective fields were
preferentially selected.
Interviews were continued in each group until saturation of ideas was
achieved. Results of each interview were captured using handwritten notes and
audio digital recording. Data were stored anonymously to protect identities of
interviewees, and recordings will be destroyed once a manuscript reporting these
results is accepted for publication. Interviewees were provided an informed
consent form, but a signature was not required because a waiver of
documentation of informed consent was obtained from the University of New
Mexico Institutional Review Board.
Audio recordings and handwritten notes were reviewed for themes and
summarized. The organized interview data were then carefully reviewed by the
author to determine the feasibility of PPI reduction interventions and inform their
development. Issues and themes related to PPI prescribing and to potential

14
interventions designed to reduce inappropriate prescribing were identified from
reviewing the interview notes and audio recordings.
Aim 2- Electronic health record (EHR) data analysis
This aim was designed to quantify trends in PPI use and the extent of PPI
overuse. To do this, we examined inpatient EHR data from the local UNMH
database and from the HealthFacts national database. The local UNMH clinical
database query was validated with manual chart reviews of ~1% of all charts
without a PPI-justifying diagnostic code. Specifically, the objective of this aim
was to determine local and national trends regarding: (1) the proportion of
inpatient encounters associated with appropriate versus potentially inappropriate
PPI prescriptions over time; and (2) the distribution of patient and provider
characteristics and diagnoses associated with PPI prescriptions. Both databases
include aggregate data on inpatient encounters.
Based on interviews with local experts, FDA approved indications and
published clinical guidelines, we compiled a list of diagnostic codes that justify
PPI prescriptions. Diagnostic codes were captured for: GERD, esophagitis,
gastritis, duodenitis, GI bleed, esophageal varices, helicobacter pylori infection,
dyspepsia, and Zollinger Ellison syndrome. No diagnostic codes are available to
capture NSAID gastric ulcer dual antiplatelet bleeding prophylaxis, but these
indications were captured on validation chart reviews. Specifically, presence of
at least one of the following ICD-9 and ICD-10 codes associated with the hospital
encounters was used as criteria for justifying PPI prescription:
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1. Gastro-esophageal reflux disease (non-erosive)- ICD-9: 530.81, ICD10: K21.9
2. Erosive/ulcerative esophagitis– ICD-9: 530.10, 530.11, 530.12, 530.19,
530.2, ICD-10: K20.8, K20.9, K21.0, K22.1, K22.10, K22.11
3. Eosinophilic esophagitis- ICD-9: 530.13, K20.0
4. Upper gastrointestinal hemorrhage- ICD-9: 456.0, 456.20, 530.21,
530.82, 531.0, 531.2, 531.4, 531.6, 532.0, 532.2, 532.4, 532.40,
532.41, 532.6, 533.0, 533.2, 533.4, 533.6, 534.0-, 534.2-, 534.4-,
534.6-, 535.01, 535.11, 535.21, 535.31, 535.41, 535.51, 535.61,
535.71, 578, ICD-10: I85.01, I85.11, K22.11, K25.0, K25.2, K25.4,
K25.6, K26.0, K26.2, K26.4, K26.6, K27.0, K27.2, K27.4, K27.6, K28.0,
K28.4, K29.01, K29.21, K29.31 K29.41, K29.51, K29.61, K29.71,
K29.81, K29.91, K31.811, K92.0, K92.1, K92.2
5. Gastroduodenal ulcer(s)- ICD-9: 531-, 532-, 533-, V12.71, ICD-10:
K25-, K26-,K27-, Z87.11
6. Helicobacter pylori infection- ICD-9: 41.86, ICD-10: B96.81
7. Dyspepsia- ICD-9: 536.8, K30
8. Zollinger Ellison syndrome- ICD-9: 251.5, ICD-10: E16.4
9. Barrett’s esophagus: ICD-9: 530.85, ICD-10: K22.7Local UNM Hospital database query
For analysis of local data, we performed a query of the clinical database
that supports the University of New Mexico Hospital’s electronic health records
(UNMH EHR), followed by manual chart reviews to validate the database
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information. The inclusion criteria for the query included: all adult (age ≥ 18)
inpatient encounters from the UNMH EHR since October 1, 2015 associated with
at least 2 days of consecutive PPI administration during the hospital encounter.
For each of the included encounters we collected the following variables:
1. Encounter numbers (FINs)
2. Patient age
3. Patient gender
4. Admission and discharge time stamps
5. Clinical service and location time stamps
6. PPI dosages, routes of administration and administration time stamps
(for all of the following PPIs: omeprazole, pantoprazole, esomeprazole,
dexlansoprazole and lansoprazole) during each encounter
7. Presence of PPI prescription (omeprazole, pantoprazole,
esomeprazole, dexlansoprazole or lansoprazole) ordered at time of
discharge
8. Presence of PPI prescription (omeprazole, pantoprazole,
esomeprazole, dexlansoprazole or lansoprazole) entered as a home
medication at time of admission
9. All ICD-10 and ICD-9 diagnostic codes affiliated with hospital encounter

Each encounter was coded as either having an appropriate “PPI justifying”
diagnosis, or not having such a diagnosis. Encounters with no justifying
diagnosis were considered to be potentially inappropriate prescriptions.
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We randomly selected 100 charts for manual chart review using the
simple random sampling function in SAS from the pool of all encounters in the
UNMH EHR database that lacked any PPI justifying diagnosis (n=4,916). The
charts were selected using a random computerized sampling process stratified
by year of admission. All charts were reviewed independently by two reviewers,
who were primary investigator JL and a third year Internal Medicine resident who
was trained for this task by JL. All discrepancies between data abstraction were
reviewed in person and resolved.
The chart reviews were used to determine provider rationales for PPI
prescriptions, to estimate the percent of potentially inappropriate PPI encounters
identified by database queries that can be confirmed inappropriate by manual
chart review, and to assess the validity of the data from our local EHR database
query. Inter-rater reliability for determination of PPI appropriateness by the chart
reviewers was calculated. In addition, the chart review process for the final 50
charts was timed with a stopwatch, allowing us to determine the feasibility of
using manual chart reviews as a future pharmacy-driven intervention to screen
for inappropriate PPI prescriptions in a hospital setting in real-time.
Criteria for determining that an inpatient encounter has appropriate PPI
administration by chart review included evidence of any of the following: (1) acute
GI bleed, (2) GERD, (3) acute gastroduodenal ulcer disease, (4) acute
esophagitis, (5) Barrett’s esophagus, (6) stress ulcer/bleeding prophylaxis in the
setting of either NSAID use or dual antiplatelet therapy, or (7) evidence that the
patient was taking a PPI at home for any of these indications. Remote (>3

18
months since event) history of gastroduodenal ulcers or GI bleed was not
considered an appropriate indication for PPI therapy.
The data from this local query were analyzed descriptively to determine
overall trends in PPI prescription at our local institution. After the validation
process was complete, the total proportion of encounters with inappropriate PPI
prescription during their hospital stay was calculated. We also calculated the
odds ratio of being discharged home with a new and inappropriate prescription
for a PPI after exposure to an inpatient Intensive Care Unit.
National HealthFacts Database Query
HealthFacts is a national-level, de-identified clinical database of all
patients from US Cerner customers that includes EHR data from over 355 million
patient encounters, about 19 million of which are inpatient hospital encounters
from over 300 hospitals. Cerner Corporation is a supplier of health information
technology, services, devices and hardware in use at over 27,000 facilities
around the world. The results of the national query of de-identified Cerner
HealthFacts database allowed us to estimate national trends of PPI overuse in
hospital settings. The case inclusion criteria for this query was: all inpatient
encounters of adults (> 18 years) from the Cerner EHR over the past 17 years
associated with PPI administration during the hospital encounter. For each of the
included encounters we collected data on the same 10 variables listed above, as
well as characteristics of the included hospitals.
Similar to the analysis of the local UNM EHR database, the national
database was analyzed descriptively to determine national trends in PPI
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prescription practices, and estimated proportion of PPI prescriptions without a
justifying diagnosis was calculated. All aggregate data from both local and
national databases were analyzed using SAS (version 9.4).
Aim 3- Provider surveys
We (JL and TW) developed an 18 question survey that took approximately
5 minutes to complete, and we requested voluntary participation from all licensed
practitioners at UNMH that provide care for adults, including residents, attending
physicians, and advanced practice providers, from 2 UNMH departments: (1)
Internal Medicine and (2) Family Medicine. These departments include a vast
majority of the practitioners that care for hospitalized adult patients at UNMH.
We solicited survey completion from all 420 providers in these departments, and
we attempted to increase the response rate by sending 4 sets of weekly email
reminders using different subject lines for each reminder.
The choice and design of survey questions (see Appendix B) were directly
informed by the results of the qualitative interviews discussed in the methods
section of Aim 1. We assessed provider characteristics: (1) specialty, (2) level of
training, and (3) years of clinical experience. We also assessed knowledge of
PPI risks and indications, and provider attitudes towards potential elements of a
PPI reduction intervention. The knowledge questions addressed: (1) knowledge
of PPI risks including the increased risk of clostridium difficile infection and
hospital acquired pneumonia, and (2) knowledge of evidence based PPI
indications and appropriate alternatives for hospitalized patients. We also
evaluated attitudes towards the following PPI reduction interventions: (1) a
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required indication for PPI orders, (2) phone calls from a pharmacist regarding
unjustified PPI orders, and (3) clinical decision support encouraging appropriate
PPI use.
Providers were solicited to complete the survey in electronic and paper
form. REDCap software was used to invite survey recipients to participate by
following a link in a survey solicitation email. Each survey link was unique to
each survey target so the REDCap system could track responders and send out
survey reminders only to non-responders and partial responders. The paper
version of the survey was distributed to all non-responders from the electronic
survey distribution. Providers were given an option on the survey of indicating
that they never or very rarely prescribe PPIs to any patients. In email and
through in-person solicitations, providers were requested to be sure not to
complete the survey more than once.
Survey results were analyzed descriptively to determine the specific gaps
in knowledge regarding PPI risks and indications and the distribution of
knowledge gaps by provider level of training (i.e. attending versus resident),
years of clinical experience, and medical specialty. Between group and within
group differences in the dependent variables (PPI knowledge and opinions
regarding PPI reduction interventions) were compared using ANOVA for
quantitative rating scale items and chi-square analysis for dichotomous items.
Group comparisons were performed between medical specialty groups and as a
function of provider experience, specialty, and provider type. These results were
reviewed by primary investigator JL to inform the development of an educational
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strategy and to determine which intervention elements are most likely to be
successfully adopted at UNMH. All survey data were analyzed using SAS
(version 9.4).

RESULTS
AIM 1- Interviews
Interviews were completed with 7 individuals at the University of New
Mexico Health Sciences Center. Two interviews were conducted with local
pharmacy leaders, 2 with local information technology leaders, and 3 with locally
recognized Internal Medicine content experts.
Pharmacy Interviews
Interviewed pharmacists were consistent in citing: (1) acute GI bleed, (2)
erosive esophagitis or gastritis, (3) helicobacter pylori infection, and (4) known
history of GERD as appropriate indications for PPI therapy in hospitalized
patients. Both interviewees recommended that ordering providers consider
antacid alternatives, such as calcium carbonate or H2 receptor antagonists
(H2RAs) for acute symptoms of acid reflux, and H2RAs as first line alternatives
for stress ulcer prophylaxis. They cited evidence of safer side effect profiles and
similar efficacy as reasons for these recommendations. Regarding methods for
weening hospitalized patients off PPIs, they recommended gradual down-titration
of dose overlapped with starting H2RAs. Both interviewees expressed interest
and willingness to assist in formalizing such a titration protocol in a standardized
electronic form to assist providers and pharmacists in making this transition safe
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and comfortable for patients. The interviewees believed that PPIs are grossly
over-prescribed at our institution, especially for symptoms such as dyspepsia,
heartburn, and for stress ulcer prophylaxis in both critically-ill and non-critically ill
patients.
They believed that requiring providers to select a PPI indication at the time
of electronic order entry would be feasible and very helpful at improving PPI use
locally. They pointed out that this tactic was recently implemented with
antibiotics at our hospital. The new approach has been hugely successful in
terms of tracking drug ordering practices and reducing inappropriate antibiotic
use. Because an “other indication” option was included, providers have been
willing to adopt this practice locally.
Both interviewees also suggested that floor-based pharmacy staff could
screen PPI orders for appropriateness, and that they could also contact providers
directly to negotiate alternative treatment plans for potentially unnecessary PPI
orders. It was made clear that such a process would only be feasible if the total
number of PPI orders to be reviewed on a daily basis was manageable -- one
interviewee indicated that reviewing less than 15-20 orders per day would
probably be feasible from a pharmacist work-load standpoint.
Information Technology Interviews
IT experts were asked if the appropriateness of PPI orders could be
determined by aggregate database queries or manual chart reviews. Both
interviewees indicated that any attempt to make a determination from aggregate
EHR data would require chart review validation. The concerns they expressed
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included: (1) the lag time between provider documentation and diagnostic coding,
(2) the poor quality of provider documentation, (3) the poor quality of diagnostic
code capturing, and (4) the lack of access that we have to medical records
outside of our hospital system. It was expressed that even manual chart reviews
would have limitations, especially for determining whether a patient truly carries a
particular diagnosis if they are followed as an outpatient at an outside clinic or
hospital system.
The IT experts interviewed were very supportive of instituting the use of
clinical decision support to encourage appropriate PPI use. They noted that
education can only go so far in changing provider practice habits and thus
stronger interventions would likely be necessary. Both interviewers supported
the plan of requiring a PPI indication at the time of order entry, but they indicated
that making such a change in the electronic physician ordering process for PPIs
would require clear evidence of PPI overuse at our institution. They advised that
an attempt to investigate and quantify this overuse be attempted with both
aggregate EHR queries and manual chart reviews. If a required indication
system was built, IT experts indicated it would be easy to create a daily report
that would query the EHR for any PPIs ordered with non-approved indications
selected. A report could then be used by pharmacists to review potentially
inappropriate orders and contact physicians to negotiate alternative therapies.
Internal Medicine Provider Interviews
Internal Medicine content experts cited acute GI bleed, esophagitis/
gastritis, and helicobacter pylori eradication as clearly appropriate indications for
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use of PPIs. Two of the providers believed that continuation of a previously
prescribed PPI was a valid indication, while a third believed that withholding a
home PPI during hospitalization to prevent adverse effects such would be
reasonable and safe most of the time. One provider believed PPIs were
appropriate for stress ulcer prophylaxis in high risk patients only, one believed
H2RAs would be more appropriate in this setting, and a the third believed that
stress ulcer prophylaxis in general is not supported by good evidence and should
not be done routinely.
For GERD, all 3 providers believed that safer and nearly as effective
alternatives should be preferentially used as first line therapy, such as antacids
as-needed and H2RAs. Dyspepsia and ulcer prophylaxis in the setting of
anticoagulant use were also cited as conditions for which H2RAs should be
preferentially used as first line therapy. Regarding specific PPI alternatives, the
providers recommended H2RAs, in particular famotidine and ranitidine, calcium
carbonate, sucralfate, aluminum-magnesium hydroxide and deglycyrrhizinated
licorice. Twice a day dosing with famotidine was noted to be particularly effect
when patients have nighttime reflux symptoms. In terms of dosing regimens,
H2RAs were considered more appropriate for scheduled therapy, whereas asneeded dosing is preferred for the antacids. When asked about strategies for
weaning patients off PPIs, all 3 providers recommended similar regimens that
work well for their patients. For patients on twice daily PPI therapy they
recommended transitioning to once daily for 2 weeks then transitioning to asneeded/on demand therapy, and for patients on once daily PPIs one of the
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providers recommended going to an every-other-day regimen for 2 weeks
followed by on demand/as-needed.
The providers also reported having success with transitioning patients
from PPIs to H2RAs as a means to discontinuing PPIs. As for means to reduce
inappropriate PPI use at our institution, all 3 providers recommended increasing
provider education and awareness, requiring an indication at the time of order
entry, and removing PPIs from electronic order-sets used by the various
departments at our institution. It was brought up that some of these order-sets
might have pre-checked PPI orders embedded and that providers could be
ordering PPIs unknowingly as a result. Other suggested tactics included: (1) a 1
week hard stop for PPI orders, (2) a nursing form that facilitates screening of PPI
orders at the time of transfer from an ICU, (3) creating local standard of care
treatment pathways for GERD and SUP, and (4) adding PPIs orders to a quality
dashboard on provider sign out sheets. One provider suggested that presenting
a local case involving a PPI-related complication in the setting of unnecessary
PPI use could be particularly impactful.
Aim 2- EHR data analysis
A total of 9,064 local UNMH encounters and 860,863 national HealthFacts
encounters met the inclusion criteria of adult inpatient hospitalizations associated
with at least 48 hours of PPI therapy. The hospital characteristics, patient
characteristic and encounter characteristics are shown in Table 3.
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Local UNMH EHR- Aggregate Database
From October 2015 through October 2017 41,584 adult inpatient
encounters occurred at UNMH, a 556 bed level 1 trauma center in the urban
Southwest. Of these encounters, 9,064 (22%) were associated with at least 48
hours of PPI therapy and were included in the analysis (Table 3). These
encounters involved 6,763 patients, with an average age of 58 (SD 16.2), 45%
female, 38% non-Hispanic white, 43% Hispanic, and 14% Native American.
The encounters had a 5.8-day median length of stay and were associated
with an average of 6.5 days (SD 8.8) of PPI therapy. Forty-five percent of the
encounters involved patients that had previously been prescribed a PPI by a
provider within the UNMH system prior to admission. In 13% of the encounters
patients were given a new, first time prescription for a PPI at the time of
discharge. Fifty-three percent of the administered PPI doses were given by
mouth or feeding tube (PO) and 47% were given intravenously (IV), whereas
73% of encounters received a PO PPI and 49% received an IV PPI. In terms of
PPI brands, the most commonly received PPI was pantoprazole which was given
to 98% of encounters, followed by omeprazole (16%), esomeprazole (4%),
lansoprazole (1%) and rabeprazole or dexlansoprazole (<1%) (Table 4).
The diagnostic categories associated with 9,064 PPI encounters are shown in
Table 4. A majority of encounters (n=4,916, 54%) had no associated diagnostic
code that could justify PPI use, and were considered potentially inappropriate.
The PPI-justifying diagnostic code categories were: GERD (25%), followed by
acute GI bleed (22%), gastroduodenal ulcer (9%), erosive esophagitis (7%),
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Table 3: Characteristics of Hospitals and Encounters Associated with PPIs

Time Frame
Age (mean ±SD, years)
Length of Stay (median)
Days of PPI therapy (mean ±SD)
Gender
Race/Ethnicity

Bed size range

Census Region

Urban vs Rural Hospital

Female
Male
African American
Asian
Caucasian (non-Hispanic)
Hispanic
Native American
Other
<5
6-99
100-199
200-299
300-499
500+
Midwest
Northeast
South
West
Rural
Urban

National HealthFacts
n=860,863
Dec 14’ - Dec 16'
2 years
63 (±17)
4
5.9 (±20.4)
53%
47%
15%
2%
76%
<1%
1%
5%
2%
10%
17%
14%
31%
26%
21%
21%
37%
21%
22%

78%

Local UNMH
n=9,064
Oct 15' - Oct 17'
2 years
59 (±16)
6
6.5 (±8.8)
45%
55%
3%
2%
38%
43%
14%
<1%
556 Beds

West

Urban
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Barrett’s esophagus (1%), helicobacter pylori infection (0.8), dyspepsia,
eosinophilic esophagitis, and Zollinger-Ellison syndrome (<1%).
Data on the ordering clinical service and associated department was
available for 8,705 of the total 9,064 encounters (96%). The distribution of PPI
encounters and percent with justifying diagnoses by ordering department and
clinical service are given in Table 5. The departments with the most PPI
associated encounters were Internal Medicine (n=4,862), followed by Surgery
(n=1,579) and Family Medicine (n=649). Of the Internal Medicine encounters,
the most common specialties involved were Hospital Medicine (n=2,456) and
Critical Care Medicine (n=1,564).
The percent of PPI associated encounters without a justifying diagnosis
varied by department, with lower a percent found in Family Medicine (45%,
n=649), Internal Medicine (47%, n=486), Emergency Medicine (51%, n=152)
and Psychiatry (51%, n=303) and a higher percent found in Urology (79%, n=
225), Orthopedics (72%, n=190), Surgery (69%, n=1,579), and OB/GYN (69%,
n=142), and Neurosurgery (68%, n=369). Within the Department of Internal
Medicine, the Oncology (68%, n=469) and Cardiology (61%, n=338) clinical
services had a higher percent of unjustified PPI encounters than the Medical
Intensive Care (48%, n=1,564) and Hospital Medicine (40%, n=2,456) services.
Within the Department of Surgery, clinical services with a higher percent of
unjustified PPI encounters included Ear/Nose/Throat (71%, n=63), Elective
Surgery (70%, n=638), Emergency Surgery (70%, n=541) and those with a
relatively lower percent included Trauma Surgical Intensive Care (60%, n=113),
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Table 4: Characteristics Associated with PPI Use for Inpatient Encounters that Received PPIs*
National- Healthfacts
n=860,863
Time Frame
Days of PPI therapy
(mean ±SD)
PPI Brand

PPI associated
diagnoses

Pantoprazole
Omeprazole
Esomeprazole
Lansoprazole
Rabeprazole
Dexlansoprazole
No justifying diagnosis
GERD
GI Ulcer
GI Bleed
Erosive esophagitis
Barrett's esophagus
Dyspepsia
Helicobacter pylori infection
Eosinophilic esophagitis
Zollinger-Ellison syndrome

OR for inappropriate PPI if ordered by ICU* (95% CI)
Estimated percent of encounters with inappropriate PPI use**

Local- UNMH
n=9,064

Dec 14’ through Dec ‘16
2 years

Oct ‘15 through Oct ‘172 years

5.9 (±20)

6.5 (±9)

89%
8%
3%
4%
0.01%
0.02%
65%
27%
4%
6%
2%
1%
0.4%
0.3%
0.03%
0.01%

98%
16%
4%
1%
0.04%
0.08%
54%
25%
9%
22%
7%
1%
0.6%
0.8%
0.04%
0.02%

1.21 (1.20 to 1.23)

1.53 (1.38 to 1.69)

38%

32%

*OR from logistic regression model, predictor variable: first PPI ordered by ICU; Controlling for age, race, gender, and LOS.
**Calculated by multiplying % with no justifying diagnosis by % inappropriate from chart review (59%).
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Table 5. Percent of Encounters with Unjustified PPI Order by Department
and Subspecialty at UNMH

Department*

Subspecialty

Urology
Orthopedics
Surgery
ENT
Elective Surgery
Emergency Surgery
Vascular
TSI
CT Surgery
Outpatient Surgery
OB/GYN
Neurosurgery
Neurology
Psychiatry
Emergency Medicine
Internal Medicine
Heme/med Oncology
Cardiology
MICU
Hospital Medicine
Family Medicine

PPI associated
encounters

Percent without
justifying
diagnosis

225
190
1,579
63
638
541
90
113
37
54
142
369
234
303

79%
72%
69%
71%
70%
70%
67%
60%
60%
57%
68%
68%
64%
51%

152

51%

4,862
467
338
1,564
2,456
649

47%
68%
61%
48%
40%
45%

*Data on ordering department available for 96% (8,702) of the 9,064 PPI
encounters.
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Cardiothoracic Surgery (60%, n=37), and Outpatient Surgery (57%, n=54).
During the 25 month study period, the monthly percent of all encounters
associated with PPI use ranged from 19% to 25% (mean=22%, SD=1.7) with a
very slight but clinically insignificant overall downward trend (Figure 1).
Figure 1:

A linear regression model of months since October 2015 predicting percent of
encounters with a PPI estimated an overall decrease in PPI use of only 0.1% per
month (R2=0.19, p=0.03).
A logistic regression model was used to determine whether an ICU
initiating PPI therapy predicts unjustified PPI use. The predictor variables used
in this model included ICU order versus not, patient age in years, gender, race,
and hospital length of stay. Controlling for age, gender, race and length of stay,
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ICU-initiated PPI status increased the odds of the PPI therapy being
inappropriate by about 53% (OR 1.53, 95% CI: 1.38 to 1.69, p<0.01). Age (OR
0.996, 95% CI 0.994 to 0.999) and gender (OR 1.164, 95% CI 1.068 to 1.267))
both had statistically significant but small predictive effects in the model.
Local UNMH EHR -- Manual Chart Review
Of the 4,916 potentially inappropriate inpatient UNMH PPI encounters,
stratified by year, 100 were randomly selected for manual chart review by two
reviewers (primary investigator JL and a third year Internal Medicine resident).
All encounters involved unique patients (no patients with duplicate encounters).
Chart Reviewer 1 spent an average of 2 minutes 20 seconds (SD 53 seconds)
determining whether the use of PPIs associated with each encounter was
appropriate, and Reviewer 2 spent an average of 3 minutes and 5 seconds (SD
98 seconds). The Cohen’s Kappa for inter-rater reliability between reviewers in
determining PPI appropriateness was 0.54 (95% CI 0.37 to 0.71).
Documented reasons for PPI orders and assessments of PPI order
appropriateness are summarized in Table 6. In total, 59% of the reviewed
inpatient encounters were determined to have inappropriate PPI use. The most
common reasons for inappropriate PPI use were: (1) unnecessary stress ulcer
prophylaxis (26%), (2) continuation of inappropriate home PPI (17%), and (3) the
treatment of symptoms including nausea, sore throat, and first line treatment of
heartburn (10%).
Of the 41% of patients determined to have received PPIs appropriately,
the most common indication was treatment of chronic GERD (35% of the 100
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Table 6: Reasons for PPI Orders by Chart Review in 100 Patients Without
Justifying Diagnoses*
Home PPI Orders
Taking a home PPI prior to admission
Home PPI without justification
Home PPI for Barrett's esophagus
Home PPI for peptic ulcer
Home PPI for esophagitis
Home PPI for GERD
Failed a trial of H2RA as first line prior to PPI
Home PPI for ulcer prophylaxis

52%
18%
2%
4%
4%
32%
0%
5%

Inpatient PPI orders
Appropriate PPI orders
Inpatient PPI given for acute GI bleed
Inpatient PPI given for GERD
Failed a trial of H2RA as first line prior to PPI
Inpatient PPI given for acute gastroduodenal ulcer disease
Inpatient PPI given for acute esophagitis
Inpatient PPI given for Barrett's esophagus
Inpatient PPI given for appropriate ulcer prophylaxis
Inappropriate PPI orders
Inpatient PPI given for history of varices
Inpatient PPI given inappropriately for ulcer prophylaxis
Inpatient PPI given for symptoms (nausea, heartburn, sore throat)
Inpatient PPI given for prior resolved indication
Unjustified home PPI continued during hospitalization
Inpatient PPI given for unknown reason
PPI was continued after ICU stay for ICU stress prophylaxis
Patient discharged with new inappropriate PPI prescription

41%
3%
35%
2%
1%
1%
2%
2%
59%
1%
26%
10%
3%
17%
11%
9%
14%

*Charts randomly selected from 4,916 encounters in the UNMH database
without a justifying diagnosis.
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sampled). All other indications were much less common, but included: 9
encounters with acute GI bleed, acute esophagitis, Barrett’s esophagus, acute
gastroduodenal ulcer, and appropriate ulcer prophylaxis. An H2RA was
attempted prior to initiation of PPI therapy for GERD treatment in only 2 of the 35
patients with GERD.
Fifty-two patients were already taking a PPI at home prior to admission. A
majority (32/52) of these patients were taking a PPI for GERD, but 18 of the 52
patients had no documented justification for an outpatient PPI prescription in
either inpatient or outpatient clinical notes. Of the 32 patients taking a PPI at
home prior to admission for long term GERD treatment, none had evidence in
outpatient notes that an H2RA had been tried previously as first line therapy or
that weening from a PPI had ever been attempted after a period of treatment.
Twenty-two patients not taking a home PPI had at least one day of
exposure to an ICU during their inpatient encounter. Of these 22 patients, 15
(68%) were given a PPI for ICU stress ulcer prophylaxis. In 9 of these 15 patients
(60%) the PPI was continued even after leaving the ICU for a lower level of care,
and 5 of these patients (33%) were discharged from the hospital with a new
inappropriate PPI prescription with no end of treatment date. Similarly, 14 of all
48 patients not previously on a home PPI (29%) were discharged home with a
new inappropriate PPI prescription.
The estimate for the percent of UNMH PPI encounters associated with
inappropriate PPI use is 32%. This is the product of 54% of all 9,064 encounters
with no justifying diagnostic code and 59% confirmed inappropriate by manual

35
chart review. The estimate for the percent of PPI encounters given a PPI for
GERD is 44%, which combines the manual chart review findings with the
aggregate data findings.
National HealthFacts EHR data
From January 2000 through December 2016 the National Cerner HealthFacts
database included 21,683,803 adult inpatient encounters from 324 hospitals
across the country. Of these encounters, 3,892,878 (18%) were associated with
PPI administration and were included in the analysis of PPI use over time (Figure
2). During this 17 year study period the monthly percent of all encounters
associated with PPI use ranged from 8% to 35% (mean=20%, SD=6), including a
steeply increase rate from 2000 to 2006, with a peak around 2006, then a very
large precipitous drop around 2009, and finally a steeply increasing trajectory
since 2016 (Figure 2). The drop in 2009 correlated with a sudden doubling of the
total number of encounters and hospitals included in the HealthFacts database.
From December 2014 through December 2016, 4,389,633 adult inpatient
encounters from 262 hospitals occurred in the HealthFacts database, of which
860,863 were associated with PPI administration. These encounters involved a
total 717,430 patients, with an average age of 63 (SD 17), 53% female, 76%
white, 15% African American, and <5% Hispanic, Native American and Asian.
Characteristics of the hospitals and patient encounters for comparison with 2
years of UNMH PPI encounter data are summarized in Table 3.
The December 2014 through December 2016 encounters had a 4 day
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Figure 2:
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median length of stay and were associated with an average of 6 days (SD 20) of
PPI therapy. In terms of PPI brands, the most commonly received PPI was
pantoprazole, which was given to 89% of encounters, followed by omeprazole
(8%), lansoprazole (4%), esomeprazole (3%) and rabeprazole or
dexlansoprazole (<0.1%) (Table 4).
Diagnostic code data was available for 841,998 (98%) of all inpatient PPIassociated encounters from December 2014 through December 2016. The
diagnostic categories associated with these encounters are shown in Table 4. A
majority of these encounters (65%) had no associated diagnostic code that could
justify PPI use. The most common PPI-justifying diagnostic code category that
was associated with PPI encounters was GERD (27%), followed by GI bleed
(6%), gastroduodenal ulcer (4%), erosive esophagitis (2%), Barrett’s esophagus
(1%), dyspepsia (0.4%), helicobacter pylori infection (0.3%), eosinophilic
esophagitis and Zollinger-Ellison syndrome (<0.1%).
A logistic regression model determined whether any exposure to an ICU
during the hospital encounter predicts unjustified PPI use. The independent
variables used in the model included ICU exposure, age in years, gender, race,
and length of stay. Controlling for age, gender, race and length of stay, ICUinitiated PPI status increased the odds of the PPI therapy being inappropriate by
21% (OR 1.21, 95% CI 1.20 to 1.23, p<0.01) (Table 4). Age (OR 0.99, 95% CI
0.990 to 0.991), and female gender (OR 0.88, 95% CI 0.873 to 0.889) had
statistically significant but small predictive effects of no clinical importance.
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Taking the product of the 65% of the December 2014 through December
2016 PPI-associated encounters without a justifying diagnosis in the HealthFacts
database and the 59% of charts confirmed to be inappropriate on manual chart
review gives an estimate that 38% of all encounters associated with PPIs involve
inappropriate PPI use nationwide.
AIM 3- Provider surveys
Surveys were sent to 389 providers in the departments of Family and
Community Medicine and Internal Medicine at UNMH. Thirty-one of the originally
intended 420 providers were not sent a survey as they had either left the
institution or were determined to not hold active faculty positions in either
department. Of 203 survey respondents (52%), 40 were excluded for returning
incomplete surveys with at least one survey item left unanswered, leaving 163
complete survey respondents (42%) that were included for analysis. The 163
providers included: 87 (54%) attendings, 14 (9%) fellows, 56 (34%) residents and
6 (4%) nurse practitioners or physician assistants (NP/PAs). Thirty-eight (23%) of
the providers were from the Department of Family/Community Medicine (FM) and
125 (77%) were from the Department of Internal Medicine (IM). The providers
included 14 different specialties and subspecialties, the most common including
non-specialized hospital and outpatient Internal Medicine (54%), non-specialized
Family Medicine (23%), Pulmonary/Critical Care (7%), Cardiology (4%),
Nephrology (3%) and Infectious Disease (3%). The 93 attendings and NP/Pas
had an average of 16 (range 43) years of clinical experience and an average of
60% (range 90%) of their work effort involved clinical duties. The resident
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physicians were in 1st year (39%), 2nd year (36%), and 3rd year (25%) levels of
training.
The results for survey questions on 11-point (0 to 10) rating scales are
given in Table 7, partitioned by provider level of training and department. For a
majority of survey questions, the average responses did not vary much in
magnitude (i.e., small Cohen’s d effect sizes) or did not statistically significantly
vary by level of provider training or by department with a few exceptions
described below. Rating scale means for each item and group are shown with
95% confidence intervals and with standard deviations (SD).
For overall PPI use, providers reported prescribing PPIs moderately often
(mean = 5.3, SD 2.7) and prescribing or supervising an average of 4.2 (SD 5.7)
PPI orders per week of clinical service. Providers reported considering a PPI
prescription for a patient but prescribing an alternative instead less than half the
time (mean rating = 3.6, SD 2.3). Providers believed that PPIs are overprescribed more than half the time (mean rating = 6.1, SD 1.6). “Overprescription” was defined as prescribing a drug when it is not necessary or when
a safer alternative is available.
The breakdown of PPI use by indication for the 159 providers that
prescribe PPIs in their practice is given in Table 8. These numbers represent
averages of the reported percent of each provider’s PPI orders that are for a
given indication. The most commonly reported indications for PPI use included
GI bleeding (35%) or GERD (30%), followed by ulcer or bleeding prophylaxis
(18%), esophagitis (10%), and helicobacter pylori eradication (4%). Of the 18%

Table 7a: Mean (95% CI) (SD) Provider Responses for 14 Rating-scaled Survey Questions by Training Level

All
(N=163)

Residents
(n=56)

Fellows
(n=14)

Attendings
(n=87)

NP/PAs
(n=6)

1. How many PPI prescriptions or
orders have you written during
your most recent week of clinical
service?

4.2
(3.3 to 5.1)
(5.7)

4.0
(3.0 to 5.1)
(3.9)

1.4
(0.5 to 2.4)
(1.7)

4.9
(3.3 to 6.4)
(7.1)

2.2
(0.2 to 4.1)
(1.8)

0.16
(max d=0.68)

2. About how often have you, or
residents under your direct
supervision, prescribed or ordered
a PPI in the past 6 months?
(Items: 2 – 3: 0-Never, 5
Moderately often, 10-Extremely
often)

5.3
(4.9 to 5.7)
(2.7)

6.0
(5.3 to 6.6)
(2.4)

5.3
(3.4 to 7.1)
(3.2)

4.9
(4.3 to 5.5)
(2.7)

5.0
(2.2 to 7.8)
(2.7)

0.13
(max d=0.43)

3. About how often have you, or
residents under your supervision,
considered prescribing or ordering
a PPI during the past 12 months
and then ended up prescribing an
alternative medication?

3.6
(3.2 to 3.9)
(2.3)

3.6
(3.1 to 4.2)
(2)

3.2
(1.9 to 4.5)
(2.3)

3.6
(3.0 to 4.1)
(2.5)

3.8
(1.7 to 6)
(2)

0.93
(max d=0.28)

4. Based on your experience, to
what extent do you believe that are
PPIs over-prescribed?
(Items 4 – 11: 0-Never, 5-About
half the time, 10-Always)

6.1
(5.9 to 6.4)
(1.6)

5.8
(5.3 to 6.4)
(1.9)

6.1
(5.4 to 6.7)
(1.1)

6.3
(6.0 to 6.6)
(1.4)

7.3
(5.9 to 8.8)
(1.4)

0.12
(max d=0.90)

5. Based on your experience, how
often do you believe that PPIs
cause a serious adverse event?

3.1
(2.9 to 3.4)
(1.7)

3.3
(2.8 to 3.8)
(1.8)

3.2
(2.5 to 3.9)
(1.3)

3.0
(2.6 to 3.3)
(1.7)

4.0
(1.7 to 6.3)
(2.2)

0.43
(max d=0.51)

Question

ANOVA
P-value

40

41

Table 7a (cont.)
All
(N=163)

Residents
(n=56)

Fellows
(n=14)

Attendings
(n=87)

NP/PAs
(n=6)

6. How often do you consider a risk of
increasing clostridium difficile infection
before prescribing a PPI?

4.5
(4.0 to 5.0)
(3.2)

4.3
(3.4 to 5.2)
(3.2)

4.3
(2.6 to 6) (2.9)

4.5
(3.8 to 5.2)
(3.3)

6.0
(2.5 to 9.5)
(3.3)

0.67
(max d=0.52)

7. How often do you discuss a risk of
increasing clostridium difficile infection
with a patient before prescribing them a
PPI?

2.1
(1.7 to 2.6)
(2.7)

2.2
(1.4 to 2.9)
(2.8)

1.4
(0.1 to 2.6)
(2.2)

2.2
(1.6 to 2.8)
(2.8)

2.5
(0.0 to 5.6)
(2.9)

0.72
(max d=0.43)

8. How often do you consider a risk of
increasing hospital acquired
pneumonia before prescribing a PPI?

3.0
(2.6 to 3.5)
(2.9)

2.4
(1.7 to 3.0)
(2.5)

2.6
(0.8 to 4.5)
(3.2)

3.4
(2.7 to 4.0)
(3.1)

4.7
(1.7 to 7.6)
(2.8)

0.10
(max d=0.87)

9. How often do you discuss a risk of
increasing hospital acquired
pneumonia with a patient before
prescribing a PPI?

1.7
(1.3 to 2.1)
(2.5)

1.3
(0.7 to 1.9)
(2.3)

1.9
(0.0 to 3.8)
(3.3)

1.9
(1.4 to 2.5)
(2.5)

1.7
(0.0 to 3.6)
(1.9)

0.54
(max d=0.25)

6.1
(5.7 to 6.6) (3)

5.8
(5.0 to 6.6)
(3)

6.1
(4.4 to 7.9) (3)

6.4
(5.7 to 7) (3)

6.0
(3.3 to 8.7)
(2.5)

0.78
(max d=0.20)

3.8
(3.3 to 4.2)
(3.1)

3.6
(2.8 to 4.3)
(2.8)

3.7
(2.0 to 5.4) (3)

3.8
(3.1 to 4.5)
(3.3)

4.2
(1.2 to 7.2)
(2.9)

0.95
(max d=0.21)

Question

10. How often do you prescribe an
H2RA as an alternative to a PPI for the
first line treatment of GERD?
11. How often do you prescribe an
H2RA as an alternative to a PPI for the
first line therapy in ulcer prophylaxis?

ANOVA
P-value
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Table 7a (cont.)

All
(N=163)
(CI) (SD)

Residents
(n=56)

Fellows
(n=14)

Attendings
(n=87)

NP/PAs
(n=6)

ANOVA
P-value

12. How comfortable would you be with
Powerchart requiring you to select an
indication before you can order a PPI?
(Items 12 – 14: 0-Not comfortable at all,
5-Somewhat comfortable, 10-Very
comfortable)

6.0
(5.5 to 6.5)
(3.3)

5.9
(5.0 to 6.8)
(3.4)

4.4
(2.6 to 6.1)
(3.0)

6.1
(5.4 to 6.8)
(3.3)

8.3
(5.6 to 11)
(2.6)

0.08
(max d=1.39)

13. How comfortable would you be with
receiving a recommendation from a
pharmacist suggesting that you change
your PPI order to something else in
certain situations?

7.4
(7.0 to 7.8)
(2.8)

7.7
(7.1 to 8.4)
(2.5)

6.6
(4.5 to 8.8)
(3.7)

7.2
(6.6 to 7.8)
(2.8)

8.2
(5.2 to
11.1) (2.8)

0.47
(max d=0.49)

14. How comfortable would you be with
using an electronic PPI order set in
Powerchart that provides clinical decision
support text regarding the appropriate
indications for PPIs and options for
alternative medications?

6.6
(6.1 to 7.1)
(3.2)

7.4
(6.7 to 8.1)
(2.7)

4.6
(2.9 to 6.3)
(3.0)

6.2
(5.5 to 6.9)
(3.4)

9.0
(6.9 to
11.1) (2.0)

0.002*
(max d=1.48)

Question
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Table 7b: Mean (95% CI) (SD) Provider Responses for 14 Survey Questions by
Department

All
(N=163)

Internal
Medicine
(n=125)

Family
Medicine
(n=38)

ANOVA
P-value

1. How many PPI prescriptions or orders
have you written during your most
recent week of clinical service?

4.2
(3.3 to 5.1)
(5.7)

4.3
(3.2 to 5.3)
(6.1)

3.9
(2.3 to 5.4)
(4.6)

0.71
(d=0.07)

2. About how often have you, or
residents under your direct supervision,
prescribed or ordered a PPI in the past 6
months?
(Items: 2 – 3: 0-Never, 5-Moderately
often, 10-Extremely often)

5.3
(4.9 to 5.7)
(2.7)

5.4
(5.0 to 5.9)
(2.7)

4.8
(4.0 to 5.7)
(2.6)

0.22
(d=0.23)

3. About how often have you, or
residents under your supervision,
considered prescribing or ordering a PPI
during the past 12 months and then
ended up prescribing an alternative
medication?

3.6
(3.2 to 3.9)
(2.3)

3.5
(3.1 to 3.9)
(2.3)

3.7
(2.9 to 4.4)
(2.2)

0.78
(d=0.09)

4. Based on your experience, to what
extent do you believe that are PPIs
over-prescribed?
(Items 4 – 11: 0-Never, 5-About half
the time, 10-Always)

6.1
(5.9 to 6.4)
(1.6)

6.1
(5.8 to 6.4)
(1.6)

6.3
(5.7 to 6.8)
(1.6)

0.59
(d=0.12)

5. Based on your experience, how often
do you believe that PPIs cause a
serious adverse event?

3.1
(2.9 to 3.4)
(1.7)

3.1
(2.8 to 3.4)
(1.7)

3.2
(2.6 to 3.8)
(1.8)

0.70
(d=0.06)

6. How often do you consider a risk of
increasing clostridium difficile infection
before prescribing a PPI?

4.5
(4.0 to 5.0)
(3.2)

4.8
(4.2 to 5.4)
(3.3)

3.5
(2.6 to 4.5)
(2.9)

0.04*
(d=0.42)

7. How often do you discuss a risk of
increasing clostridium difficile infection
with a patient before prescribing them a
PPI?

2.1
(1.7 to 2.6)
(2.7)

2.2
(1.7 to 2.8)
(2.9)

1.8
(1.1 to 2.6)
(2.3)

8. How often do you consider a risk of
increasing hospital acquired pneumonia
before prescribing a PPI?

3.0
(2.6 to 3.5)
(2.9)

3.0
(2.5 to 3.5)
(3.0)

3.0
(2.1 to (3.9)
(2.7)

Question

0.40
(d=0.15)

0.99
(d=0)
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Table 7b (cont.)

Question
9. How often do you discuss a
risk of increasing hospital
acquired pneumonia with a
patient before prescribing a
PPI?
10. How often do you prescribe
an H2RA as an alternative to a
PPI for the first line treatment of
GERD?
11. How often do you prescribe
an H2RA as an alternative to a
PPI for the first line therapy in
ulcer prophylaxis?
12. How comfortable would you
be with Powerchart requiring you
to select an indication before
you can order a PPI?
(Items 12 – 14: 0-Not
comfortable, 5-Somewhat
comfortable, 10-Very
comfortable)
13. How comfortable would you
be with receiving a
recommendation from a
pharmacist suggesting that you
change your PPI order to
something else in certain
situations?
14. How comfortable would you
be with using an electronic PPI
order set in Powerchart that
provides clinical decision
support text regarding the
appropriate indications for PPIs
and options for alternative
medications?

All
(N=163)

Internal
Medicine
(n=125)

Family
Medicine
(n=38)

1.7
(1.3 to 2.1)
(2.5)

1.7
(1.2 to 2.2)
(2.6)

1.7
(1.0 to 2.4)
(2.1)

6.1
(5.7 to 6.6)
(3.0)

5.8
(5.3 to 6.4)
(3.0)

7.1
(6.2 to 8)
(2.7)

0.02*
(d=46)

3.8
(3.3 to 4.2)
(3.1)

3.5
(3.0 to 4.1)
(3.0)

4.5
(3.5 to 5.6)
(3.2)

0.08
(d=0.32)

6.0
(5.5 to 6.5)
(3.3)

6.3
(5.7 to 6.9)
(3.4)

5.1
(4.1 to 6.1)
(3.0)

7.4
(7.0 to 7.8)
(2.8)

7.5
(6.9 to 8)
(2.9)

7.2
(6.4 to 7.9)
(2.4)

6.6
(6.1 to 7.1)
(3.2)

6.7
(6.1 to 7.2)
(3.2)

6.3
(5.3 to 7.4)
(3.2)

ANOVA
P-value
0.98
(d=0)

0.06
(d=0.37)

0.56
(d=0.11)

0.55
(d=0.13)
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Table 8a. Mean Provider Reports of the % of Their PPI Prescriptions by Indication and by Training Level

Of all your prescriptions for PPIs, what % are for:

All **
Residents Fellows Attendings NP/PAs
(N=159)
(n=56)
(n=14)
(n=83)
(n=6)

ANOVA
p-value

GI bleed

35

39

27

32

55

0.20

esophagitis

10

8

9

10

24

0.24

H pylori infection

4

3

3

2

21

<0.01*

continuing home med

1

1

0

1

0

0.86

GERD OR heartburn

30

30

30

30

29

0.99

GERD- 1st line therapy

39

45

25

37

28

0.27

GERD- that failed H2RA

35

35

52

33

29

0.33

GERD- continuing home med

6

5

0

7

19

0.25

GERD other reason(s)

4

2

9

4

2

0.47

18

19

33

16

6

0.22

stress ulcer prophylaxis in an ICU patient

9

15

4

6

0

0.03

stress ulcer prophylaxis in a NON-ICU patient

5

3

10

5

4

0.61

prophylaxis in setting of high risk med(s)

4

0

19

5

2

<0.02*

3

1

1

5

0

0.51

any type of ulcer/bleeding prophylaxis

Some other reason(s)

*Statistically significant on one-way ANOVA, <0.05
**Table includes data for providers that have prescribed PPIs in the last 6 months
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Table 8b. Mean Provider Reports of the % of Their PPI Prescriptions by Indication and by Department

All **
(N=159)

Internal
Medicine
(n=122)

Family
Medicine
(n=37)

ANOVA
p-value

GI bleed

35

36

30

0.31

Esophagitis

10

12

4

0.04

H pylori infection

4

4

3

0.87

Continuing home med

1

1

0

0.54

GERD OR heartburn

30

24

49

<0.01*

GERD- 1st line therapy

39

42

28

0.05

GERD- that failed H2RA

35

29

55

<0.001*

GERD- continuing home med

6

7

2

0.21

GERD other reason(s)

4

4

3

0.76

18

23

2

<0.01*

Stress ulcer prophylaxis in an ICU patient

9

12

1

<0.01*

Stress ulcer prophylaxis in a NON-ICU patient

5

6

1

0.11

Prophylaxis in setting of high risk med(s)

4

6

0

0.12

3

4

0

0.20

Of all your prescriptions for PPIs, what % are for:

Any type of ulcer/bleeding prophylaxis

Some other reason(s)

*Statistically significant on one-way ANOVA, <0.05
**Table includes data for providers that have prescribed PPIs in the last 6 months
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of PPI orders for ulcer or bleeding prophylaxis, most were for SUP for critically-ill
(ICU) patients (9%) followed by SUP for non-ICU patients (5%) and prophylaxis
in the setting of high-risk medications (4%). Fellows reported the highest use of
PPIs for high-risk medication prophylaxis (19%, p=0.01) and residents reported
the highest use for SUP in ICU patients (15%, p<0.03). The average percent of
PPI orders for SUP in ICU patients was 41% for 10 the Pulmonary/Critical Care
specialists. Providers reported using H2RAs as a first line alternative to PPIs for
SUP less than half the time (3.8, SD 3.1). IM providers reported using PPIs more
frequently than FM providers for esophagitis (12% versus 4%, p<0.04) and much
more frequently for ulcer or bleeding prophylaxis (23% versus 2%, p<0.001),
whereas FM reported more frequent use of PPIs for GERD (49% versus 24%,
p<0.001).
When asked about the percent of PPI orders for GERD that they used as
first line therapy for their patients, IM providers reported higher 1st line PPI usage
42%) than FM providers (28%) (p=0.05). Similarly, FM providers reported more
frequent use of PPIs for GERD only after H2RA treatment failure compared to IM
(55% vs 29%, p<0.01). Overall, providers reported that 39% of their PPI orders
for GERD were used as 1st line therapy and 35% were used after a failed trial of
H2RAs (Table 8). The results shown in Table 7 for 0 to 10 point response survey
questions on PPI alternatives were consistent with the findings in Table 8. FM
providers reported that they use H2RAs as first line therapy for GERD more
frequently than IM providers (7.1 vs 5.8, p=0.02, d=0.46).
Providers believed that serious adverse events are caused by PPIs about
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30% of the time (mean rating = 3.1 on a 0 to 10 scale with 5 labeled as “about
half the time”, SD=1.7). Lifetime hours of education on PPI side effects by
training level and department are given in Table 9. Most providers reported
having received very little education on PPI side effects: 45% reported 1 or hour
less of education, and 12% reported no education at all. The amount of PPI side
effect education experienced by providers was collected in categories (see Table
9), but treating hours of education as an estimate of a continuous variable puts
the average total hours education at less than 2, a finding that did not vary by
department or by level of training.
An increased risk of clostridium difficile infection with PPI therapy was
considered a little less than half of the time (mean rating=4.5, SD=3.2), with IM
providers reporting this consideration more frequently than FM providers
(mean=4.8 versus 3.5, p=0.04, d=0.42). Discussion of clostridium difficile risk
with patients was reported as rare across all levels of training and departments
(mean=2.1, SD=2.7). A consideration of increased hospital acquired pneumonia
risk with PPI therapy was reported to take place about 30% of the time (mean=3,
SD=2.9), and discussion of this risk with patients was rare (mean=1.7, SD=2.5).
Providers were more comfortable than not with the 3 proposed PPI
reduction interventions addressed by survey questions 12-14. These comfort
levels had significant variation by training level. Providers were most comfortable
with receiving pharmacist recommendations on PPI use, followed by an order-set
with clinical decision support text and least comfortable with a required PPI
indication. The mean provider comfort level with receiving pharmacist
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Table 9: % Providers Reporting Hours of Education about Proton Pump Inhibitor Side Effects by Level of Training
and Department

All

Residents

Fellows

Attendings

NP/PAs

Internal
Medicine

Family
Medicine

(N=163)

(n = 56)

(n = 14)

(n = 87)

(n = 6)

(n =125)

(n = 38)

None at all

11.7%

8.9%

0.0%

13.8%

33.3%

12.8%

7.9%

1 hour or less

45.4%

58.9%

42.9%

37.9%

33.3%

40.8%

60.5%

2 hours

24.5%

19.6%

35.7%

26.4%

16.7%

27.2%

15.8%

3 hours

8.6%

7.1%

7.1%

9.2%

16.7%

8.8%

7.9%

4 hours

2.5%

1.8%

0.0%

3.4%

0.0%

2.4%

2.6%

5 or more hours

7.4%

3.6%

14.3%

9.2%

0.0%

8.0%

5.3%

How many hours of education
on the potential side effects of
PPIs have you received overall?
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recommendations on PPI orders was 7.7 (SD=2.8), a finding that did not vary
significantly by training level or department. Mean provider comfort with an
order-set that provides clinical decision support and PPI alternative order options
was 6.6 (SD=3.2), and this finding varied by training level (p=0.002; d=1.48) with
fellows reporting the lowest level of comfort (mean=4.6, SD=3) and NP/PAs
reporting the highest level of comfort (mean=9, SD=2). Mean provider comfort
with having to select a required PPI indication prior to finalizing an electronic
order was rated as 6 (SD=3.3), with the lowest comfort level expressed by
fellows (mean=4.4, SD=3) and highest expressed by NP/PAs (mean=8.3,
SD=2.6) (p=0.08; maximum d=1.39).
A MANOVA with the design of GERD versus Ulcer Prophylaxis (within subjects)
X Training Level (n=4) (between subjects) X Department (n=2) (between
subjects) showed that the only statistically significant effect was main effect for
GERD vs. Ulcer Prophylaxis (F (1, 156) = 37.69, p < 0.001; η2=0.20 (Figure 3).
Examination of the means in Figure 3 shows that providers are significantly more
likely to report prescribing an H2 antagonist as an alternative to first line
treatment for GERD (mean = 6.53, SD = 2.98) than for ulcer prophylaxis (mean =
5.84, SD = 3.08). Mean differences that can be seen in the figure between
departments and between training levels are not statistically significantly
different.
A MANOVA with the design of “How often do you order a PPI” versus
“How often do you consider a PPI but order an alternative” (within subjects) X
Training Level (4) (between subjects) X Department (2) (between subjects) was

51
Figure 3a:
Internal Medicine Use of H2RAs as PPI Alternative for GERD versus Ulcer
Prophylaxis by Training Level

performed (Figure 4). As shown in Figure 4, providers report prescribing a PPI
(mean = 6.5, SD = 3.0) more frequently than they consider prescribing a PPI but
instead choose an alternative (mean = 3.6, SD = 2.3) (F (1, 156) = 9.56, p < 0.01;
η2=0.06). The mean differences between departments and between training
levels shown in Figure 4 are not statistically significant.
A MANOVA with the design of “How often do you believe PPIs are
overprescribed?” versus “How often do you believe PPIs cause a serious
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Figure 3b:
Family Medicine use of H2RAs as PPI Alternative for GERD versus Ulcer
Prophylaxis by Training Level

adverse event?” (within subjects) X Training Level (4) (between subjects) X
Department (2) (between subjects) showed that the only statistically significant
effect was a main effect for over-prescription versus adverse-events (F (1, 156) =
127.88, p < 0.01; η2=0.45) (Figure 5). Figure 5 shows that providers consider
PPI over-prescribing (mean = 6.1, SD = 1.7) to occur more frequently then
serious PPI adverse events (mean = 3.1, SD = 1.7). The mean differences
between departments and between training levels shown in Figure 5 are not
statistically significant.
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Figure 4a:
Internal Medicine Use of PPIs versus PPI Alternatives by Training Level
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Figure 4b:
Family Medicine Use of PPIs versus PPI Alternatives by Training Level
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Figure 5a:
Internal Medicine Perceptions of PPI Over-prescription versus Adverse Events by
Training Level
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Figure 5b:
Family Medicine Perceptions of PPI Over-prescription versus Adverse Events by
Training Level
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DISCUSION
We estimate that PPI use is unnecessary in at least 32% of PPIassociated hospital encounters at UNMH and 38% nationally. A vast majority of
the “justified” PPI use is for the first line therapy of chronic diagnoses of GERD.
Given that PPI therapy for GERD is only recommended as a short-term
intervention, we suspect that the actual extent of PPI overuse is much higher.
Furthermore, professional society guidelines that recommend PPIs as first line
therapy for GERD37,38 cite head to head efficacy studies with H2RAs as the
rationale for these recommendations without considering that the side effect
profile of PPIs makes these medications far more dangerous than the modestly
less effective alternatives. Other than chronic GERD treatment, the use of PPIs
for other FDA and professional society recommended indications is relatively
uncommon in hospitalized patients.
The most common reason for unjustified PPI use is for stress ulcer
prophylaxis, especially in critically ill patients, followed by inappropriate 1 st line
treatment of minor patient symptoms including nausea, sore throat, and
heartburn, and the continuation of unjustified home PPI prescriptions. The use of
PPIs for stress ulcer prophylaxis, even in the critically ill, has been found to be
non-efficacious in randomized controlled trials74,75, but is still a very common
practice based on our data. Initiation of PPI therapy by an ICU at our institution
increased the risk of inappropriate PPI use by about 53%, and any exposure to
ICU care nationally increases the risk of inappropriate PPI use by 21%. The
inappropriate use of PPIs for ICU stress ulcer prophylaxis commonly leads to
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inadvertent continuation of PPI therapy after the ICU stay and sometimes
indefinitely after hospital discharge, according to the results of our manual chart
reviews.
Large differences in PPI use and justifications appear to exist between
different departments and clinical care teams. Surgical specialties at our
institution had much higher rates of unjustified PPI use than non-surgical
specialties, with the highest rates found in urology (79%), orthopedics (72%), and
elective and emergency general surgery (70%). In general, specialist clinical
care teams appear to have higher rates of unjustified PPI use compared to
primary care specialties. For example, within the Department of Internal
Medicine rates of unjustified PPI use within Hematology/Oncology (68%) and
Cardiology (61%) were much higher than that of Hospital Medicine (40%). These
differences could represent different sub-specialty trends in prescription habits,
but differences in documentation practices between services is likely to
contribute as well.
Out data indicate that PPI use does not appear to have changed
substantially over the past 2 years. At our institution an average of 22% of all
hospital encounters in the past 2 years received PPIs, with a negligible
downward trend. Nationally, 20% of hospital encounters in the past 17 years are
associated with PPI use with significant variation in use patterns over time. Most
recently, since the start of 2016, PPI use appears to be increasing substantially
both locally and nationally. Over the past 17 years PPI use appears to have
fluctuated profoundly, with a gradual increase in use from 2000 to 2006, a steep
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drop off in early 2009, a gradual increase since 2010 and a steep increase since
2016. In 2009, many hospitals were added to the HealthFacts database, and the
total number of inpatient encounters included in the database roughly doubled.
The newly included patient encounters had a lower association with PPI use,
which explains the sudden 2009 drop off in percent of encounters associated
with PPIs. However it is not known if the other fluctuations in apparent PPI use
represent actual changes in clinical practice, availability of medications, or
changes in procedures and data inclusion within the HealthFacts database.
The surveys indicate that providers are more willing than not to adopt
institutionalized strategies to reduce PPI overuse, including clinical decision
support, review of PPI orders by pharmacists, and required indications. The
survey results also suggest much room for improvement in the quantity and
quality of educational interventions regarding PPI side effects and the importance
of patient counseling. Providers indicated that they have received very little
formal education on PPI side effects, mostly either none or 1 hour or less in the
span of their careers. Providers infrequently consider PPI side effects of
clostridium difficile infection and hospital acquired pneumonia prior to prescribing,
and counsel their patients on these risks even less frequently. However,
providers at our institution do believe that PPIs are being over-prescribed more
often than not, which could indicate a higher likelihood of success in educational
interventions to change prescription habits.
This study does have a number of limitations. The use of administrative
coding data to determine PPI justifications, even with validation and rate
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corrections from manual chart review, is still limited in its ability to accurately
assess provider intentions in regards to PPI ordering practices. Furthermore, the
inter-rater reliability of PPI appropriateness determinations was low with a
Cohen’s Kappa of 0.54. This was primarily due to the difficulty of manually
searching through numerous notes for evidence of physician decision making
processes regarding PPI use. Significant problems in the validity of the EHR
data may exist as well. Another limitation is that the final determination of what
constitutes PPI appropriateness is not entirely clear because discrepant
indications for PPI use remain between FDA approvals, different professional
societies, and contradictions in the extant literature. In regards to the survey
data, a major limitation is that the sample of providers used in this study is limited
to a single institution and to 2 departments. It is possible that opinions of
providers at our institution are not representative of those of the entire nation or
the world, and this limits the generalizability of these results.
Overall, based on the results of this study, interventions to reduce the
inappropriate use of PPIs in the hospital setting seem quite feasible. The
feasibility of having a pharmacist review PPI orders routinely is supported by the
fact that determining PPI appropriateness by manual chart review only takes
about 2 to 3 minutes on average, as well as by the willingness of providers to
adopt such an intervention. The persistent magnitude in the problem of PPI
overuse also supports the feasibility of PPI reduction in a hospital setting.
A PPI reduction plan will be developed at our institution based on the
results of our interviews, provider surveys, aggregate data analyses and manual
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chart reviews. Educational interventions and clinical decision support will be
developed to specifically target and reduce sources of PPI overuse, especially
routine use in stress ulcer prophylaxis, continuation of unnecessary home
prescriptions, and treatment of mild patient symptoms when safer alternatives
are readily available. Rates of unjustified PPI use by clinical service will be used
to track improvements over time as PPI reduction strategies are gradually
implemented. Rates of specific hospital acquired infections that are known to be
increased by PPI exposure will also be tracked over time to determine whether
PPI reduction in the hospital setting can reduce the incidence of these
devastating and increasingly common iatrogenic diseases.
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Appendix A
Interview Guides
Semi-structured Interview Guide- Information Technology
1. Determining appropriateness of proton pump inhibitor prescriptions
a. How, if at all, could the appropriateness of PPI prescriptions be determined by
chart review?
b. How, if at all, could appropriateness of PPI prescriptions be determined through
aggregate database queries?
2. Methods to decrease inappropriate PPI use
a. Do you have any ideas for how PPI overuse could be decreased using
information technology?
b. What do you think about the use of clinical decision support to encourage
appropriate PPI use? Would it work?
c. Would it be feasible or acceptable at UNMH to create a careset or powerplan that
required inpatient providers to select an appropriate indication for oral PPI
prescription prior ordering the drug?
Semi-structured Interview Guide- Inpatient Pharmacy
1. Appropriate indications for proton pump inhibitors

a. What are appropriate indications for prescribing PPIs to hospitalized
patients?
b. What inpatient diagnoses for which PPIs are prescribed would you recommend
providers consider an alternative for first line therapy instead?
2. Methods to discontinuing PPIs and alternatives to PPIs
a. What are the alternatives to PPI use that can be used to treat these diagnoses?
b. What is the best method, in terms of dosing and timing of administration, to ween
a patient off of a PPI?
c. What is the best way, in terms of dosing and timing of administration, to transition
a patient from a PPI to an H2 receptor antagonist?
3. Methods to decrease inappropriate PPI use
a. Do you have any ideas for how PPI overuse could be decreased?
b. What do you think about the use of clinical decision support to encourage
appropriate PPI use?
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c. Would it be feasible to create a pharmacy driven protocol for reviewing inpatient
PPI prescriptions for appropriateness and to have pharmacists recommend
transitioning to H2 receptor antagonists or discontinuation?
d. Would pharmacy support the use of a careset or powerplan that requires
providers to select an appropriate PPI indication from a drop down menu prior to
initiating the prescription?
Semi-structured Interview Guide- Internal Medicine
1. Appropriate indications for proton pump inhibitors

a. What are appropriate indications for prescribing PPIs to hospitalized
patients?
b. What inpatient diagnoses for which PPIs are prescribed would you recommend
providers consider an alternative for first line therapy instead?

c. How, if at all, could the appropriateness of PPI prescriptions be
determined by chart review?
2. Alternatives to PPIs
a. What are the alternatives to PPI use that can be used to treat these diagnoses?
b. What starting dose, dose titration, and duration of therapy do you prescribe for
H2 receptor antagonists for GERD?
c. What starting dose, dose titration, and duration of therapy do you prescribe for
other antacids such as Maalox or GI cocktails?
d. What is the best method, in terms of dosing and timing of administration, to ween
a patient off of a PPI?
e. What is the best way, in terms of dosing and timing of administration, to transition
a patient from a PPI to an H2 receptor antagonist?

3. Methods to decrease inappropriate PPI use
a. Do you have any ideas for how PPI overuse could be decreased?
b. What do you think about the use of clinical decision support to encourage
appropriate PPI use? Would it work?
c. What do you think about the use of a system, such as a care set or powerplan,
which requires providers to select an appropriate PPI indication from a drop
down menu prior to initiating the prescription?
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Appendix B
Provider Survey

1. About how often have you, or residents under your direct supervision, prescribed or ordered a proton
pump inhibitor (PPI) in the past 6 months?
0
Never

1

2

3

4

5
Moderately
often

6

7

8

9

10
Extremely
often

2. Of PPI orders or prescriptions that you have written (or supervised)
during the past 6 months, what % have been for:
(Please provide your best estimate for each)
(if zero, write in “0”)
_____ % stress ulcer prophylaxis in a non-ICU patient
_____ % stress ulcer prophylaxis in an ICU patient
_____ % GI bleed
_____ % gastroesophageal reflux disease (GERD) OR heartburn
_____ % esophagitis
_____ % Helicobacter pylori infection
_____ % Other reason(s)
_________________________________________ name other reason(s)
3. Of PPI orders or prescriptions that you have written (or supervised)
during the past 6 months for GERD or heartburn, what % have been for:
_____ % first line therapy
_____ % failed H2 receptor antagonist
_____ % Other reason(s)
_________________________________________ name other reason(s)
“Over-prescription” means that a drug is prescribed when it is not necessary or when a safer alternative
drug is available.

4. Based on your experience, to what extent do you believe that PPIs are overprescribed?
0
Never

1

2

3

4

5
About half
the time

6

7

8

9

10
Always

5. Based on your experience, how likely do you believe that PPIs are to cause a serious adverse event?
0
Never

1

2

3

4

5
About half
the time

6

7

8

9

10
Always
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6. How often do you consider a risk of increasing clostridium difficile infection before prescribing a PPI?
0
Never

1

2

3

4

5
About half
the time

6

7

8

9

10
Always

7. How often do you discuss a risk of increasing clostridium difficile infection with a patient before
prescribing them a PPI?
0
Never

1

2

3

4

5
About half
the time

6

7

8

9

10
Always

8. How often do you consider a risk of increasing hospital acquired pneumonia before prescribing a PPI?
0
Never

1

2

3

4

5
About half
the time

6

7

8

9

10
Always

9. How often do you discuss a risk of increasing hospital acquired pneumonia with a patient before
prescribing them a PPI?
0
Never

1

2

3

4

5
About half
the time

6

7

8

9

10
Always

10. How often do you prescribe an H2 receptor antagonist such as ranitidine as an alternative to a PPI for
the first line treatment of GERD?
0
Never

1

2

3

4

5
6
7
8
9
10
About half
Always
the time
11. How often do you prescribe an H2 receptor antagonist such as ranitidine as an alternative to a PPI for
the first line therapy in ulcer prophylaxis?
0
Never

1

2

3

4

5
About half
the time

6

7

8

9

10
Always

12. How comfortable would you be with Powerchart requiring you to select an indication before you
can order a PPI?
0
1
2
3
4
5
6
7
8
9
10
Not
Somewhat
Completely
comfortable
comfortable
comfortable
13. How comfortable would you be with receiving a recommendation from a pharmacist suggesting that
you change your PPI order to something else in certain situations?
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0
1
Not
comfortable

2

3

4

5
Somewhat
comfortable

6

7

8

9

10
very
comfortable

An “order set” in Powerchart is a group of orders in one window where users can select from a list of
order options.
14. How comfortable would you be with using an electronic PPI order set in Powerchart that provides
clinical decision support text regarding the appropriate indications for PPIs and options for alternative
medications?
0
1
Not
comfortable

2

3

4

5
Somewhat
comfortable

6

7

8

9

10
Very
comfortable

15. Since beginning your job here at UNM, have you received any formal education, such as a lecture or
required online training, on the potential side effects of PPIs?
 Yes
 No
16. What is your specialty?
 Internal Medicine
 Family Medicine
17. What is your level of training?









R1
R2
R3
R4
R5
Fellow
Attending
Advanced Practice Provider (NP or PA)

18. During the past 6 months, what percentage of your work effort has involved clinical activities?
______% of my work time involved clinical activities
19. How many years of clinical experience do you have after completing training?
______ years
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